mRNA vaccines and therapeutics demand rigorous, stage-specific analytical control. From plasmid DNA starting materials to mRNA drug substance and lipid nanoparticle (LNP) drug product, each step introduces unique quality risks that can impact safety, efficacy, and regulatory success.

With access to our whitepaper and additional assets, you will explore how CE provides a high-resolution, regulator-aligned analytical platform to characterize critical quality attributes (CQAs) across the entire mRNA manufacturing workflow. 

Download now to:

  • Learn how CE enables high-resolution analysis of plasmid DNA topology, linearized DNA templates, mRNA drug substance, and mRNA-LNP drug product using a single, integrated platform
  • Discover CE-based approaches for measuring mRNA purity and integrity, poly(A) tail length and distribution, 5’ capping efficiency, and encapsulation efficiency—critical parameters for potency and stability
  • See how CE supports process optimization, comparability studies, and stability assessments with reproducible, regulator-aligned data that scales from development to manufacturing

 

Download now

Request information